Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Mukherji

Showing results (1-10 of 197) with videos related to

Pageof 20
Sort By:
The Lancet. Oncology|June 16, 2025
CONTACT-02 and beyond: rethinking immunotherapy strategies in metastatic prostate cancerDeborah Mukherji, Aurelius Omlin
Chinese Clinical Oncology|September 14, 2020
Germline mutations and prostate cancer: is it time to change treatment algorithms?Talar Telvizian, Deborah Mukherji
Urology|October 20, 2022
Editorial CommentMohammed Shahait, Deborah Mukherji
Expert Opinion on Pharmacotherapy|June 24, 2010
Pixantrone for the treatment of aggressive non-Hodgkin lymphomaDeborah Mukherji, Ruth Pettengell
Expert Opinion on Drug Discovery|March 14, 2013
A review of in vitro and in vivo models of oesophageal and gastric cancerDeborah Mukherji, Tim Benepal
Expert Opinion on Investigational Drugs|February 27, 2009
Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancerDeborah Mukherji, James Spicer
Drugs of Today (Barcelona, Spain : 1998)|February 4, 2010
Pixantrone maleate for non-Hodgkin's lymphomaDeborah Mukherji, Ruth Pettengell
European Urology|June 20, 2020
Living Longer and Better with Advanced Prostate CancerDeborah Mukherji, Aurelius Omlin, Carmel Pezaro
World Journal of Gastroenterology|March 12, 2014
Sequencing of treatment in metastatic colorectal cancer: where to fit the targetSally Temraz, Deborah Mukherji, Ali Shamseddine
Critical Reviews in Oncology/Hematology|March 28, 2016
Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistanceSally Temraz, Deborah Mukherji, Ali Shamseddine
Pageof 20

Showing results (1-10 of 197) with videos related to

Sort By:
Pageof 20
The Lancet. Oncology|June 16, 2025
CONTACT-02 and beyond: rethinking immunotherapy strategies in metastatic prostate cancerDeborah Mukherji, Aurelius Omlin
Chinese Clinical Oncology|September 14, 2020
Germline mutations and prostate cancer: is it time to change treatment algorithms?Talar Telvizian, Deborah Mukherji
Urology|October 20, 2022
Editorial CommentMohammed Shahait, Deborah Mukherji
Expert Opinion on Pharmacotherapy|June 24, 2010
Pixantrone for the treatment of aggressive non-Hodgkin lymphomaDeborah Mukherji, Ruth Pettengell
Expert Opinion on Drug Discovery|March 14, 2013
A review of in vitro and in vivo models of oesophageal and gastric cancerDeborah Mukherji, Tim Benepal
Expert Opinion on Investigational Drugs|February 27, 2009
Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancerDeborah Mukherji, James Spicer
Drugs of Today (Barcelona, Spain : 1998)|February 4, 2010
Pixantrone maleate for non-Hodgkin's lymphomaDeborah Mukherji, Ruth Pettengell
European Urology|June 20, 2020
Living Longer and Better with Advanced Prostate CancerDeborah Mukherji, Aurelius Omlin, Carmel Pezaro
World Journal of Gastroenterology|March 12, 2014
Sequencing of treatment in metastatic colorectal cancer: where to fit the targetSally Temraz, Deborah Mukherji, Ali Shamseddine
Critical Reviews in Oncology/Hematology|March 28, 2016
Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistanceSally Temraz, Deborah Mukherji, Ali Shamseddine
Pageof 20